IV Ganaxolone active

Phase 2

MARINUS (MRNS)

Phase 2

Development Phase

Upcoming Catalysts

Historical Events

Regulatory Approvals

No Catalysts Found

No catalyst events have been recorded for this drug yet.

Competitive Landscape

0 competitors in Status Epilepticus

View Full Landscape

Drug Information

Target Indication

Status Epilepticus

Clinical Trial

NCT03350035

Last updated: 12/13/2025

Patent & Exclusivity

No patent data available. Pre-approval drugs may not have Orange Book listings.

Source: FDA Orange Book

Regulatory Approvals

EMA7/26/2023

Ztalmy

Ztalmy is indicated for the adjunctive treatment of epileptic seizures associated with cyclin-dependent kinase-like 5 (CDKL5) deficiency disorder (CDD) in patients 2 to 17 years of age. Ztalmy may be continued in patients 18 years of age and older.

Orphan

View on EMA

Drug Science

Mechanism of action & safety profile

Developer

MRNS

MARINUS

Healthcare•North America•NASDAQ

Related Pipeline

ganaxolonePhase 3

Epilepsies, Partial

View full pipeline

Get Catalyst Alerts

Receive weekly digests of upcoming catalysts